Apex Biotechnology Corp (1733) — Cash Flow-to-Debt Ratio
Apex Biotechnology Corp (1733) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of NT$5.19 Million could theoretically repay 0% of its total liabilities (NT$494.69 Million) in one year. See 1733 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Apex Biotechnology Corp Cash Flow-to-Debt Ratio (2002–2024)
Historical debt coverage capacity for Apex Biotechnology Corp across 23 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Apex Biotechnology Corp.
Annual Cash Flow-to-Debt Ratio for Apex Biotechnology Corp (2002–2024)
Year-by-year debt coverage analysis for Apex Biotechnology Corp. Check 1733 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.55x | NT$328.67 Million | NT$595.70 Million | ▲ +19.8% |
| 2023 | 0.46x | NT$230.39 Million | NT$500.07 Million | ▲ +1106.2% |
| 2022 | 0.04x | NT$26.62 Million | NT$696.81 Million | ▼ -80.5% |
| 2021 | 0.20x | NT$179.87 Million | NT$916.91 Million | ▼ -29.7% |
| 2020 | 0.28x | NT$280.60 Million | NT$1.01 Billion | ▼ -31.4% |
| 2019 | 0.41x | NT$462.52 Million | NT$1.14 Billion | ▲ +442.7% |
| 2018 | 0.07x | NT$67.57 Million | NT$901.70 Million | ▲ +9.5% |
| 2017 | 0.07x | NT$70.83 Million | NT$1.03 Billion | ▼ -82.4% |
| 2016 | 0.39x | NT$298.06 Million | NT$768.49 Million | ▼ -37.2% |
| 2015 | 0.62x | NT$472.15 Million | NT$764.69 Million | ▲ +79.6% |
| 2014 | 0.34x | NT$267.60 Million | NT$778.52 Million | ▼ -43.0% |
| 2013 | 0.60x | NT$484.77 Million | NT$803.47 Million | ▼ -13.0% |
| 2012 | 0.69x | NT$509.67 Million | NT$735.18 Million | ▼ -1.4% |
| 2011 | 0.70x | NT$273.45 Million | NT$388.76 Million | ▼ -51.6% |
| 2010 | 1.45x | NT$465.59 Million | NT$320.60 Million | ▲ +12.6% |
| 2009 | 1.29x | NT$391.29 Million | NT$303.31 Million | ▼ -4.9% |
| 2008 | 1.36x | NT$299.96 Million | NT$221.21 Million | ▼ -23.8% |
| 2007 | 1.78x | NT$364.62 Million | NT$204.80 Million | ▼ -4.2% |
| 2006 | 1.86x | NT$363.71 Million | NT$195.73 Million | ▲ +95.7% |
| 2005 | 0.95x | NT$212.14 Million | NT$223.36 Million | ▼ -44.1% |
| 2004 | 1.70x | NT$218.54 Million | NT$128.64 Million | ▼ -31.4% |
| 2003 | 2.48x | NT$302.25 Million | NT$122.00 Million | ▲ +178.0% |
| 2002 | 0.89x | NT$79.49 Million | NT$89.21 Million | — |